Related Experiment Video

Updated: Sep 24, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Cost effectiveness of beta blocker therapy for patients with chronic severe heart failure in Ireland

M Barry1

  • 1National Centre for Pharmacoeconomics, St James's Hospital, Dublin. mbarry@stjames.ie

Irish Medical Journal
|August 13, 2002
PubMed

Insights

Adding carvedilol to standard heart failure treatment significantly improves patient outcomes and is highly cost-effective in Ireland. This beta-blocker therapy offers a favorable incremental cost-effectiveness ratio per life year gained.

Area of Science:

  • Cardiology
  • Health Economics

Background:

  • Heart failure management consumes significant healthcare resources, with hospital admissions being a major cost driver.
  • Beta-blockers, like carvedilol, have demonstrated safety and efficacy in chronic heart failure when added to standard therapies such as ACE inhibitors.
  • Reducing hospital admission rates with beta-blockers is anticipated to improve cost-effectiveness.

Purpose of the Study:

  • To determine the cost-effectiveness of adding the beta-blocker carvedilol to standard therapy for patients with severe heart failure.
  • To evaluate the economic impact of carvedilol in the Irish healthcare setting.

Main Methods:

  • Economic modeling techniques were employed.
  • Irish cost data was utilized for the analysis.
  • Sensitivity analysis was performed under various assumptions.

Main Results:

  • The incremental cost-effectiveness ratio (ICER) for carvedilol therapy was 1,560 Euro per life year gained (LYG).
  • Sensitivity analysis revealed an ICER range from 1,560 Euro/LYG to 7,322 Euro/LYG.
  • Carvedilol therapy demonstrated significant cost-effectiveness in the Irish healthcare context.

Conclusions:

  • Carvedilol therapy is safe and effective for patients with severe chronic heart failure.
  • Carvedilol therapy represents a highly cost-effective treatment option within the Irish healthcare system.
  • The findings support the integration of carvedilol into standard care for severe heart failure to optimize resource allocation.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...